Monday, April 29, 2024 11:25:51 AM
Annovis Bio Shares Sink After Buntanetap Study Misses Endpoint
Mentioned: ANVS
By Dean Seal
Shares of Annovis Bio plummeted after the phase 2/3 study of its drug candidate buntanetap as a treatment for Alzheimer's disease missed a primary endpoint.
The stock was down 59% at $7.32 on heavy volume, with several pauses for volatility. Shares were trading around $14.57 a year ago and have swung between a high of $22.49 and a low of $5.42 in the past 12 months.
The clinical-stage drug-platform company said Monday that the phase 2/3 trial showed buntanetap producing a significantly higher rate of improvement in cognition assessment scores at each treatment dose relative to a placebo.
But another endpoint in the study, examining the drug's impact based on an assessment called Clinician's Global Impression of Change, was not met, with no statistically significant difference observed across all dosing groups of patients compared with a placebo group.
Annovis said the assessment is more subjective, allowing for a greater placebo effect as patients and caregivers were likely hopeful for a change.
The company said it plans to conduct a phase 3 study to confirm and expand its findings in an 18-month disease-modifying trial.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 29, 2024 11:18 ET (15:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Recent ANVS News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 10:05:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 09:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:32:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:05:24 PM
- Annovis Announces New Publication in a Peer-Reviewed Journal • GlobeNewswire Inc. • 05/21/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:05:46 PM
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:11:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:03:33 PM
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 09:12:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:11:19 PM
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders • GlobeNewswire Inc. • 05/06/2024 11:30:00 AM
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/29/2024 02:10:00 PM
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters… • IH Market News • 02/28/2024 12:08:14 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/12/2024 07:00:23 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:05:20 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:33:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:31:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:29:31 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM